Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee S Simon

Showing results (21-30 of 131) with videos related to

Pageof 14
Sort By:
JAMA|May 29, 2014
Trial evidence and approval of therapeutic agentsAllan M Green, Lee S Simon
The Annals of Pharmacotherapy|December 14, 2004
Analysis of aspirin-associated risks in healthy individualsChin Hur, Lee S Simon, G Scott Gazelle
Osteoarthritis and Cartilage Open|December 31, 2024
Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?Nancy E Lane, Lee S Simon, Jeyanesh Tambiah
Cancer|June 29, 2004
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individualsChin Hur, Lee S Simon, G Scott Gazelle
Rheumatology (Oxford, England)|January 12, 2022
What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?Kathleen S Bingham, Vibeke Strand, Lee S Simon, et al.
Pain Practice : the Official Journal of World Institute of Pain|August 15, 2013
Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskRobert Andrew Moore, Sheena Derry, Lee S Simon, et al.
Rheumatology (Oxford, England)|July 14, 2021
What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?Kathleen S Bingham, Vibeke Strand, Lee S Simon, et al.
Arthritis and Rheumatism|August 31, 2004
Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosusJoel Schiffenbauer, Bevra Hahn, Michael H Weisman, et al.
Lupus Science & Medicine|June 28, 2020
Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic reviewVibeke Strand, Lee S Simon, Alexa Simon Meara, et al.
The Journal of Rheumatology|January 3, 2014
OMERACT 11: international consensus conference on outcome measures in rheumatologyLee S Simon, Vibeke Strand, Clifton O Bingham, et al.
Pageof 14

Showing results (21-30 of 131) with videos related to

Sort By:
Pageof 14
JAMA|May 29, 2014
Trial evidence and approval of therapeutic agentsAllan M Green, Lee S Simon
The Annals of Pharmacotherapy|December 14, 2004
Analysis of aspirin-associated risks in healthy individualsChin Hur, Lee S Simon, G Scott Gazelle
Osteoarthritis and Cartilage Open|December 31, 2024
Slow acting medications for progressive and painful knee osteoarthritis. How do we assess the benefit to risk of these potentially novel therapies?Nancy E Lane, Lee S Simon, Jeyanesh Tambiah
Cancer|June 29, 2004
The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individualsChin Hur, Lee S Simon, G Scott Gazelle
Rheumatology (Oxford, England)|January 12, 2022
What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?Kathleen S Bingham, Vibeke Strand, Lee S Simon, et al.
Pain Practice : the Official Journal of World Institute of Pain|August 15, 2013
Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskRobert Andrew Moore, Sheena Derry, Lee S Simon, et al.
Rheumatology (Oxford, England)|July 14, 2021
What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?Kathleen S Bingham, Vibeke Strand, Lee S Simon, et al.
Arthritis and Rheumatism|August 31, 2004
Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosusJoel Schiffenbauer, Bevra Hahn, Michael H Weisman, et al.
Lupus Science & Medicine|June 28, 2020
Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic reviewVibeke Strand, Lee S Simon, Alexa Simon Meara, et al.
The Journal of Rheumatology|January 3, 2014
OMERACT 11: international consensus conference on outcome measures in rheumatologyLee S Simon, Vibeke Strand, Clifton O Bingham, et al.
Pageof 14